Evidence map›Paper›PMID 41993624›Full record

ArticleTheranostics2026

Anti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3.

Sarah E Glazer, Margie N Sutton, Ping Yang, Federica Pisaneschi, Manu Sebastian, Seth T Gammon, David Piwnica-Worms

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sarah E GlazerDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Margie N SuttonDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ping YangDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Federica PisaneschiDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manu SebastianDepartment of Veterinary Medicine & Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Seth T GammonDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David Piwnica-WormsDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Radioligand therapy (RLT) is an emerging oncologic strategy that uses molecularly targeted therapeutic radioisotopes to reduce tumor burden and improve survival in patients with advanced cancers. Expanding RLT to new targets and understanding its systemic immune effects could enhance its clinical impact. B7-H3 Methods: A novel IgG2a monoclonal antibody (MIL33B) was developed with high affinity for 4Ig-B7-H3 (72 picomolar) and 8- to 18-fold selectivity over soluble 2Ig-B7-H3. Target specificity was assessed using live-cell fluorescence microscopy with AF594-labeled MIL33B. Results: MIL33B demonstrated strong membranous localization using live cell fluorescence microscopy. PET-CT imaging with Conclusions: MIL33B enables selective targeting of 4Ig-B7-H3 for beta-emitting RLT, overcoming challenges posed by soluble isoforms. These findings support further investigation of MIL33B as a systemic therapeutic with immune-priming potential, either alone or in combination strategies for cancer treatment.

Indexed as

Antibodies, MonoclonalB7 AntigensNeoplasmsRadioisotopesAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunoglobulin GMicePositron Emission Tomography Computed TomographyProtein IsoformsAntibodies, MonoclonalB7 AntigensCD276 protein, humanImmunoglobulin GProtein IsoformsRadioisotopes

Identifiers

PMID41993624
PMCPMC13080693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.